Published in Curr Atheroscler Rep on October 01, 2011
Nature or the natural evolution of plaque: what matters? Maedica (Buchar) (2013) 1.67
The Swedish CArdioPulmonary BioImage Study: objectives and design. J Intern Med (2015) 0.98
Natural history of atherosclerotic disease progression as assessed by (18)F-FDG PET/CT. Int J Cardiovasc Imaging (2015) 0.88
Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Rep (2015) 0.84
Spectral CT of carotid atherosclerotic plaque: comparison with histology. Eur Radiol (2012) 0.81
Positron emission tomography of the vulnerable atherosclerotic plaque in man--a contemporary review. Clin Physiol Funct Imaging (2013) 0.80
Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis. Curr Cardiovasc Imaging Rep (2012) 0.79
Eyes on the Vulnerable. Maedica (Buchar) (2015) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Genomewide association studies and assessment of the risk of disease. N Engl J Med (2010) 11.51
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Coronary plaque disruption. Circulation (1995) 8.04
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
The limitations of risk factors as prognostic tools. N Engl J Med (2006) 5.90
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol (2010) 5.79
Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol (2009) 5.70
Imaging of atherosclerotic cardiovascular disease. Nature (2008) 4.14
Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol (2004) 3.53
Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol (2005) 3.34
Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation (2010) 2.84
The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology (2007) 2.66
Pathogenesis of atherosclerosis. J Am Coll Cardiol (2006) 2.44
Rapid mortality falls after risk-factor changes in populations. Lancet (2011) 2.27
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol (2010) 2.07
Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J (2004) 1.68
Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol (2005) 1.67
Assessing risk factors as potential screening tests: a simple assessment tool. Arch Intern Med (2010) 1.55
Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf (2008) 1.47
The efficacy of combining several risk factors as a screening test. J Med Screen (2005) 1.34
The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease--study design and objectives. Am Heart J (2010) 1.27
Relationship of carotid distensibility and thoracic aorta calcification: multi-ethnic study of atherosclerosis. Hypertension (2009) 1.03
Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA (2007) 0.99
USF1 gene variants, cardiovascular risk, and mortality in European Americans: analysis of two US cohort studies. Arterioscler Thromb Vasc Biol (2007) 0.92
Early identification of atherosclerotic disease by noninvasive imaging. Nat Rev Cardiol (2010) 0.87
The CVD paradox: mortality vs prevalence. Nat Rev Cardiol (2009) 0.85
Risk factors for near-term myocardial infarction in apparently healthy men and women. Clin Chem (2010) 0.84
High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med (2006) 14.79
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg (2006) 10.79
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med (2008) 7.95
Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA (2005) 5.83
The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol (2013) 4.81
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
Training cardiovascular fellows in cardiovascular magnetic resonance and vascular imaging; Current status following the core cardiovascular training symposium (COCATS-2) guidelines. J Am Coll Cardiol (2004) 2.67
Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging (2009) 2.56
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008) 2.52
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke (2009) 2.51
Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging (2012) 2.50
Neovascularization in human atherosclerosis. Circulation (2006) 2.44
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007) 2.32
OCT-based diagnosis and management of STEMI associated with intact fibrous cap. JACC Cardiovasc Imaging (2013) 2.31
Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation (2004) 2.30
Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med (2003) 2.29
Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol (2005) 2.23
Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation (2004) 2.16
ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol (2002) 2.14
Insights into degenerative aortic valve disease. J Am Coll Cardiol (2007) 2.09
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol (2010) 2.07
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation (2002) 2.00
Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail (2009) 1.93
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol (2013) 1.93
Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation (2007) 1.91
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 1.87
Intravascular modalities for detection of vulnerable plaque: current status. Arterioscler Thromb Vasc Biol (2003) 1.86
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arterioscler Thromb Vasc Biol (2002) 1.79
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 1.79
MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol (2010) 1.78
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arterioscler Thromb Vasc Biol (2008) 1.73
Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol (2012) 1.72
Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov (2004) 1.71
Polymorphism in APOB associated with increased low-density lipoprotein levels in both genders in the general population. J Clin Endocrinol Metab (2005) 1.71
Targeting preschool children to promote cardiovascular health: cluster randomized trial. Am J Med (2012) 1.70
Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ Res (2012) 1.68
Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J (2004) 1.68
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression withanti-apoptotic Bcl-2 and HSP47 in arterial repair. J Am Coll Cardiol (2003) 1.67
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol (2003) 1.67
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation (2004) 1.65
In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol (2011) 1.65
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail (2013) 1.61
Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. Circulation (2002) 1.60
Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation (2012) 1.60
New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol (2004) 1.59